Show simple item record

dc.contributor.authorKrop, I
dc.contributor.authorCortes, J
dc.contributor.authorMiller, K
dc.contributor.authorHuizing, M
dc.contributor.authorProvencher, L
dc.contributor.authorGianni, L
dc.contributor.authorChan, S
dc.contributor.authorTrudeau, M
dc.contributor.authorSteinberg, J
dc.contributor.authorSugg, J
dc.contributor.authorLiosatos, M
dc.contributor.authorPaton, V
dc.contributor.authorPeterson, A
dc.contributor.authorWardley, Andrew M
dc.date.accessioned2017-05-12T12:05:53Z
dc.date.available2017-05-12T12:05:53Z
dc.date.issued2017-02-14
dc.identifier.citationAbstract P4-22-08: a single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer 2017, 77 (4 Supplement):P4-22-08 Cancer Researchen
dc.identifier.issn0008-5472
dc.identifier.issn1538-7445
dc.identifier.doi10.1158/1538-7445.SABCS16-P4-22-08
dc.identifier.urihttp://hdl.handle.net/10541/620339
dc.language.isoenen
dc.relation.urlhttp://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS16-P4-22-08en
dc.rightsArchived with thanks to Cancer Researchen
dc.titleAbstract P4-22-08: a single-arm phase 2 study to assess clinical activity, efficacy and safety of enzalutamide with trastuzumab in HER2+ AR+ metastatic or locally advanced breast canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentDana-Farber Cancer Institute, Boston, MAen
dc.identifier.journalCancer Researchen


This item appears in the following Collection(s)

Show simple item record